How do varying concentrations and treatment durations of anti-PDL1 antibodies affect HCT116 cell viability, xenograft tumor size, and T cell activation, as measured by MTT assay, tumor weight, and IL-2 production, respectively?
DOI:
https://doi.org/10.61173/n49rc157Keywords:
HCT116 colorectal cancer cells, anti-PD-L1, immunotherapy, eriodictyol, interleukin-2 productionAbstract
This paper aims to explore the effect of anti-PD-L1 antibody on HCT116 colorectal cancer cells and their corresponding xenografts in a mouse model. The central hypothesis is that increasing the concentration of anti-PD-L1 antibodies and the duration of treatment will result in a reduction in cell viability, a reduction in tumour size, and an enhancement in T cell activation. The viability of the cells was evaluated through the MTT method, which quantifies metabolic activity as an indicator of cellular health. The size of the tumour was determined by weighing the excised tumours. An enzyme-linked immunosorbent assay (ELISA) was employed to evaluate T cell activation by quantifying interleukin-2 (IL-2) production. In order to establish a framework for comparison, eriodictyol, a known PD-L1 inhibitor, was used as a positive control, while an unrelated antibody served as a negative control. According to the research, the preliminary study results indicated that higher concentrations and prolonged exposure to anti-PD-L1 antibodies significantly reduced HCT116 cell viability and tumour weight, while increasing IL-2 levels, which suggests enhanced T cell activation. These results indicate a strong correlation between anti-PD-L1 antibody therapy and immune system involvement in the context of colorectal cancer. The objective of this study was to emphasise the potential of anti-PD-L1 therapy in stimulating an immune response to malignant growths. Furthermore, the necessity for optimising treatment parameters is investigated and disccussed, including dosage and duration, in order to maximise the efficacy of cancer immunotherapy. This could facilitate the use of immune checkpoint inhibitors in clinical settings, potentially improving outcomes for patients with colorectal cancer and other tumour types.References
[1] Sonia Ben Hamouda, &Khadija Essafi-Benkhadir. (2023, March 15). Interplay between Signaling Pathways and Tumor Microenvironment Components: A Paradoxical Role in Colorectal Cancer. International Journal of Molecular Sciences, 24(6), 5600. https://www.ncbi.nlm.nih.gov/pmc/articles/ PMC10057671/
[2] Merhi, M., Ahmad, F., Taib, N., Inchakalody, V., Uddin, S., Shablak, A., & Dermime, S. (2023). The complex network of transcription factors, immune checkpoint inhibitors and stemness features in colorectal cancer: A recent update. Seminars in Cancer Biology, 89, 1–17. https://doi.org/10.1016/ j.semcancer.2023.01.001
[3] Nishimura H, Nose M, Hiai H, Minato N, Honjo T. Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motifcarrying immunoreceptor. Immunity. 1999;11:141–151. [PubMed] [Google Scholar] The first demonstration that PD1 downmodulates immune responses.
[4] Dong H, et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nature Med. 2002;8:793–800. [PubMed] [Google Scholar] The crucial demonstration that PDL1 is upregulated on tumour cells and that PDL1 expression on tumour cells mediates immune resistance.
[5] Fife BT, et al. Interactions between PD-1 and PD-L1 promote tolerance by blocking the TCR-induced stop signal. Nature Immunol. 2009;10:1185–1192. [PMC free article] [PubMed] [Google Scholar]
[6] Tosolini M, Kirilovsky A, Mlecnik B, Fredriksen T, Mauger S, Bindea G, Berger A, Bruneval P, Fridman WH, Pages F, Galon J. Clinical impact of different classes of infiltrating t cytotoxic and helper cells (th1, th2, treg, th17) in patients with colorectal cancer. Cancer Res. 2011;71(4):1263–1271. doi: 10.1158/0008- 5472.CAN-10-2907. [PubMed] [CrossRef] [Google Scholar]
[7] Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pages C, Tosolini M, Camus M, Berger A, Wind P, Zinzindohoue F, et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science. 2006;313(5795):1960–1964. doi: 10.1126/ science.1129139. [PubMed] [CrossRef] [Google Scholar]
[8] Choi, Y., Seok, S. H., Yoon, H. Y., Ryu, J. H., & Kwon, I. C. (2024). Advancing cancer immunotherapy through siRNA-based gene silencing for immune checkpoint blockade. Advanced Drug Delivery Reviews, 209, 115306. https://doi.org/10.1016/ j.addr.2024.115306
[9] Kumar, P., Nagarajan, A., & Uchil, P. D. (2018). Analysis of cell viability by the MTT Assay. Cold Spring Harbor Protocols, 2018(6), pdb.prot095505. https://doi.org/10.1101/pdb. prot095505
[10] Igietseme, J. U., & Herscowitz, H. B. (1987). Quantitative measurement of T-lymphocyte activation by an enzyme-linked immunosorbent assay (ELISA) detecting interleukin-2 receptor expression. Journal of Immunological Methods, 97(1), 123–131. https://doi.org/10.1016/0022-1759(87)90114-1
[11] Liu, Y., Wu, W., Cai, C., Zhang, H., Shen, H., & Han, Y. (2023). Patient-derived xenograft models in cancer therapy: technologies and applications. Signal Transduction and Targeted Therapy, 8(1). https://doi.org/10.1038/s41392-023-01419-2
[12] Jung, J. (2014). Human Tumor Xenograft Models for Preclinical Assessment of anticancer drug development. Toxicological Research, 30(1), 1–5. https://doi.org/10.5487/ tr.2014.30.1.001
[13] Ross, S. H., & Cantrell, D. A. (2018). Signaling and function of interleukin-2 in T lymphocytes. Annual Review of Immunology, 36(1), 411–433. https://doi.org/10.1146/annurevimmunol-042617-053352
[14] Spolski, R., Li, P., & Leonard, W. J. (2018). Biology and regulation of IL-2: from molecular mechanisms to human therapy. Nature Reviews. Immunology, 18(10), 648–659. https:// doi.org/10.1038/s41577-018-0046-y
[15] Rollings, C. M., Sinclair, L. V., Brady, H. J. M., Cantrell, D. A., & Ross, S. H. (2018). Interleukin-2 shapes the cytotoxic T cell proteome and immune environment–sensing programs. Science Signaling, 11(526). https://doi.org/10.1126/scisignal. aap8112
[16] Ghaffari, S., Torabi-Rahvar, M., Aghayan, S., Jabbarpour, Z., Moradzadeh, K., Omidkhoda, A., & Ahmadbeigi, N. (2021). Optimizing interleukin-2 concentration, seeding density and bead-to-cell ratio of T-cell expansion for adoptive immunotherapy. BMC Immunology, 22(1). https://doi. org/10.1186/s12865-021-00435-7
[17] Hernandez, R., Põder, J., LaPorte, K. M., & Malek, T. R. (2022). Engineering IL-2 for immunotherapy of autoimmunity and cancer. Nature Reviews. Immunology, 22(10), 614–628. https://doi.org/10.1038/s41577-022-00680-w
[18] Raskov, H., Orhan, A., Christensen, J. P., & Gögenur, I. (2020). Cytotoxic CD8+ T cells in cancer and cancer immunotherapy. British Journal of Cancer, 124(2), 359–367. https://doi.org/10.1038/s41416-020-01048-4
[19] Chen, X., Sifakis, E. G., Robertson, S., Neo, S. Y., Jun, S., Tong, L., Min, A. T. H., Lövrot, J., Hellgren, R., Margolin, S., Bergh, J., Foukakis, T., Lagergren, J., Lundqvist, A., Ma, R., & Hartman, J. (2022). Breast cancer patient-derived whole-tumor cell culture model for efficient drug profiling and treatment response prediction. Proceedings of the National Academy of Sciences, 120(1). https://doi.org/10.1073/pnas.2209856120
[20] Kumar, P., Nagarajan, A., & Uchil, P. D. (2018b). Analysis Dean&Francis Yusi Liu of cell viability by the MTT Assay. Cold Spring Harbor Protocols, 2018(6), pdb.prot095505. https://doi.org/10.1101/pdb. prot095505
[21] Wang, W., Li, Y., Lin, K., Wang, X., Tu, Y., & Zhuo, Z. (2023). Progress in building clinically relevant patient‐derived tumor xenograft models for cancer research. Animal Models and Experimental Medicine, 6(5), 381–398. https://doi.org/10.1002/ ame2.12349
[22] Safont, G., Villar-Hernández, R., Smalchuk, D., Stojanovic, Z., Marín, A., Lacoma, A., Pérez-Cano, C., López-Martínez, A., Molina-Moya, B., Solis, A. J., Arméstar, F., Matllo, J., Díaz- Fernández, S., Romero, I., Casas, I., Strecker, K., Preyer, R., Rosell, A., Latorre, I., & Domínguez, J. (2024). Measurement of IFN-γ and IL-2 for the assessment of the cellular immunity against SARS-CoV-2. Scientific Reports, 14(1). https://doi. org/10.1038/s41598-024-51505-w
[23] Grammarly’s free grammar checker. (2024, September 5.). https://www.grammarly.com/grammar-check
Downloads
Published
Issue
Section
License
Copyright (c) 2024 by the authors.
This work is licensed under a Creative Commons Attribution 4.0 International License.
